A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.

被引：2
作者：
Krishnan, Amrita Y.
Shah, Nina
Spira, Alexander I.
Kaufman, Jonathan L.
Niesvizky, Ruben
Shah, Nirav Niranjan
Burke, John M.
Popplewell, Leslie
Martin, Thomas G.
Cheung, Julee
Matheny, Shannon L.
Leonard, John Paul
Molina, Arturo
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Virginia Canc Specialists, Fairfax, VA USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] New York Presbyterian Hosp, Cornell Campus, New York, NY USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Rocky Mt Canc Ctr, Aurora, CO USA
[8] Sutro Biopharma, San Francisco, CA USA
[9] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS7586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7586
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies
    Stein, R
    Qu, ZX
    Cardillo, TM
    Chen, S
    Rosario, A
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 2004, 104 (12) : 3705 - 3711
  • [12] Early safety and efficacy from a phase I open-label clinical study of LVGN7409 (CD40 agonist antibody) in patients with advanced or metastatic malignancies.
    Fu, Siqing
    Vandross, Andrae Lavon
    Hsu, Yi Hsin
    Shi, Naiyi
    Jiang, Lynn
    Su, Fusheng
    Wang, Jieyi
    Chan, C. Hubert
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [13] Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas
    Martin, Peter
    Furman, Richard R.
    Rutherford, Sarah
    Ruan, Jia
    Ely, Scott
    Greenberg, June
    Coleman, Morton
    Goldsmith, Stanley J.
    Leonard, John P.
    LEUKEMIA & LYMPHOMA, 2015, 56 (11) : 3065 - 3070
  • [14] STRO-002-GM2: A phase 1, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody-drug conjugate (ADC), in combination with bevacizumab in patients with advanced epithelial ovarian cancer (EOC, including fallopian tube or primary peritoneal cancers).
    Naumann, R. Wendel
    Martin, Lainie P.
    Oaknin, Ana
    Spira, Alexander I.
    Hamilton, Erika P.
    Schilder, Russell J.
    Lu, Lin
    Kuriakose, Jason
    Berman, Craig Jerome
    Molina, Arturo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [15] A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) and endometrial cancers
    Naumann, Robert Wendel
    Uyar, Denise S.
    Schilder, Russell J.
    Palumbo, Michael A.
    DeAlmeida, Venita
    Matheny, Shannon L.
    Molina, Arturo
    CANCER RESEARCH, 2019, 79 (13)
  • [16] An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors
    Xue, Liqiong
    Tang, Wenbo
    Zhou, Huan
    Liu, Mulin
    Liu, Yuanyuan
    Wang, Jinhua
    Chen, Jianfeng
    Liu, Mingyao
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [17] A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma
    Chakraborty, Rajshekhar
    Yan, Ying
    Royal, Mike
    BLOOD, 2021, 138
  • [18] A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.
    Haydon, Andrew Mark
    Kichenadasse, Ganessan
    Kirkwood, John M.
    Kaufman, Howard E.
    Buchbinder, Elizabeth Iannotti
    Ganju, Vinod
    Barve, Minal A.
    Jiang, Haifang
    Xu, Huinan
    Zhou, Xusha
    Zhu, Huan J.
    Ni, Dongyao
    Niu, Jiaxin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [19] The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
    Patel, Krish
    Rothman, Sarah
    Das, Poulomee A.
    Yee, Stephanie
    Ramachandran, Indu
    Koumenis, Iphigenia
    Cook, Terry A.
    Yuan, Ying
    Trede, Nikolaus S.
    Mattour, Ahmad Hatem
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [20] A phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies.
    Infante, Jeffrey R.
    Goel, Sanjay
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Robbins, Paul B.
    D'Angelo, Gina
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345